Derazantib; ARQ-087

Aha kemịkalụ:

(6R) -6- (2-fluorophenyl) -5,6-dihydro-N-[3-[2-[(2-methoxyethyl) amino] ethyl] phenyl]-Benzo[h] quinazolin-2-amine

Koodu Ọchịchọ:

COCCNCCC1=CC(NC2=NC=C3C[C@@H](C4=CC=CC=C4F)C5=CC=CC=C5C3=N2)=CC=C1

Koodu InChi:

InChi=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24- 10-4-5-12-2 7 (24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H ,32,33,34)/t26-/m1/s1

Igodo InChi:

KPJDVVCDVBFRMU-AREMUKBSSA-N

Okwu:

Derazantinib, ARQ-087, ARQ087, ARQ 087, 1234356-69-4

Solubility:Soluble na DMSO

Nchekwa:0 - 4 Celsius C maka obere oge (ụbọchị ruo izu), ma ọ bụ -20 Celsius maka ogologo oge (ọnwa).

Nkọwa:

Derazantinib, nke a makwaara dị ka ARQ-087, bụ onye na-emechi ọnụ nke ihe na-eme ka fibroblast growth factor receptor (FGFR) nwere ọrụ antineoplastic. FGFR inhibitor ARQ 087 na-ejikọta na ike na-egbochi ọrụ nke FGFR subtypes 1, 2 na 3. Nke a nwere ike ịkpata mgbochi nke FGFR-mediated signal transduction paths, tumor cell proliferation, tumor angiogenesis na tumor cell death in FGFR-overexpressing tumor cell . FGFR, onye na-anabata tyrosine kinase, na-edozi n'ọtụtụ ụdị cell tumor ma na-arụ ọrụ dị mkpa na mmụba cellular tumor, ọdịiche, angiogenesis na nlanarị.

Ebumnuche: FGFR